Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
Ju-Yeon Cho, Won Sohn, Dong-Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Joon Hyeok Lee
Korean J Intern Med. 2017;32(4):636-646.   Published online 2016 Nov 4     DOI: https://doi.org/10.3904/kjim.2016.096
Citations to this article as recorded by Crossref logo
Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy
Tien-Ching Lin, Yen-Cheng Chiu, Hung-Chih Chiu, Wen-Chun Liu, Pin-Nan Cheng, Chiung-Yu Chen, Ting-Tsung Chang, I-Chin Wu
World Journal of Gastroenterology.2018; 24(6): 725.     CrossRef
Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan
Fumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, Hitomi Sezaki, Norio Akuta, Shunichiro Fujiyama, Yusuke Kawamura, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Rie Mineta, Yukiko Suzuki, Hiromitsu Kumada
Journal of Gastroenterology.2018;[Epub]     CrossRef
Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
Sung Eun Kim
The Korean Journal of Internal Medicine.2017; 32(4): 631.     CrossRef